To further investigate whether PSMB10 downregulation could increase primary LSC sensitivity to chemotherapy in vivo with syngeneic normal hematopoietic and immune microenvironment, we used the MLL-AF9 (MA9) leukemia mouse model (Fig. 4F). This evidence concerns the gene MLLT3 and leukemia.